Cargando…

Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review

BACKGROUND: Long-term sedative use is prevalent and associated with significant morbidity, including adverse events such as falls, cognitive impairment, and sedation. The development of dependence can pose significant challenges when discontinuation is attempted as withdrawal symptoms often develop....

Descripción completa

Detalles Bibliográficos
Autores principales: Pollmann, André S., Murphy, Andrea L., Bergman, Joel C., Gardner, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491204/
https://www.ncbi.nlm.nih.gov/pubmed/26141716
http://dx.doi.org/10.1186/s40360-015-0019-8
_version_ 1782379601158209536
author Pollmann, André S.
Murphy, Andrea L.
Bergman, Joel C.
Gardner, David M.
author_facet Pollmann, André S.
Murphy, Andrea L.
Bergman, Joel C.
Gardner, David M.
author_sort Pollmann, André S.
collection PubMed
description BACKGROUND: Long-term sedative use is prevalent and associated with significant morbidity, including adverse events such as falls, cognitive impairment, and sedation. The development of dependence can pose significant challenges when discontinuation is attempted as withdrawal symptoms often develop. We conducted a scoping review to map and characterize the literature and determine opportunities for future research regarding deprescribing strategies for long-term benzodiazepine and Z-drug (zopiclone, zolpidem, and zaleplon) use in community-dwelling adults. METHODS: We searched PubMed, Cochrane Central Register of Controlled Trials, EMBASE, PsycINFO, CINAHL, TRIP, and JBI Ovid databases and conducted a grey literature search. Articles discussing methods for deprescribing benzodiazepines or Z-drugs in community-dwelling adults were selected. RESULTS: Following removal of duplicates, 2797 articles were reviewed for eligibility. Of these, 367 were retrieved for full-text assessment and 139 were subsequently included for review. Seventy-four (53 %) articles were original research, predominantly randomized controlled trials (n = 52 [37 %]), whereas 58 (42 %) were narrative reviews and seven (5 %) were guidelines. Amongst original studies, pharmacologic strategies were the most commonly studied intervention (n = 42 [57 %]). Additional deprescribing strategies included psychological therapies (n = 10 [14 %]), mixed interventions (n = 12 [16 %]), and others (n = 10 [14 %]). Behaviour change interventions were commonly combined and included enablement (n = 56 [76 %]), education (n = 36 [47 %]), and training (n = 29 [39 %]). Gradual dose reduction was frequently a component of studies, reviews, and guidelines, but methods varied widely. CONCLUSIONS: Approaches proposed for deprescribing benzodiazepines and Z-drugs are numerous and heterogeneous. Current research in this area using methods such as randomized trials and meta-analyses may too narrowly encompass potential strategies available to target this phenomenon. Realist synthesis methods would be well suited to understand the mechanisms by which deprescribing interventions work and why they fail. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0019-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4491204
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44912042015-07-05 Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review Pollmann, André S. Murphy, Andrea L. Bergman, Joel C. Gardner, David M. BMC Pharmacol Toxicol Research Article BACKGROUND: Long-term sedative use is prevalent and associated with significant morbidity, including adverse events such as falls, cognitive impairment, and sedation. The development of dependence can pose significant challenges when discontinuation is attempted as withdrawal symptoms often develop. We conducted a scoping review to map and characterize the literature and determine opportunities for future research regarding deprescribing strategies for long-term benzodiazepine and Z-drug (zopiclone, zolpidem, and zaleplon) use in community-dwelling adults. METHODS: We searched PubMed, Cochrane Central Register of Controlled Trials, EMBASE, PsycINFO, CINAHL, TRIP, and JBI Ovid databases and conducted a grey literature search. Articles discussing methods for deprescribing benzodiazepines or Z-drugs in community-dwelling adults were selected. RESULTS: Following removal of duplicates, 2797 articles were reviewed for eligibility. Of these, 367 were retrieved for full-text assessment and 139 were subsequently included for review. Seventy-four (53 %) articles were original research, predominantly randomized controlled trials (n = 52 [37 %]), whereas 58 (42 %) were narrative reviews and seven (5 %) were guidelines. Amongst original studies, pharmacologic strategies were the most commonly studied intervention (n = 42 [57 %]). Additional deprescribing strategies included psychological therapies (n = 10 [14 %]), mixed interventions (n = 12 [16 %]), and others (n = 10 [14 %]). Behaviour change interventions were commonly combined and included enablement (n = 56 [76 %]), education (n = 36 [47 %]), and training (n = 29 [39 %]). Gradual dose reduction was frequently a component of studies, reviews, and guidelines, but methods varied widely. CONCLUSIONS: Approaches proposed for deprescribing benzodiazepines and Z-drugs are numerous and heterogeneous. Current research in this area using methods such as randomized trials and meta-analyses may too narrowly encompass potential strategies available to target this phenomenon. Realist synthesis methods would be well suited to understand the mechanisms by which deprescribing interventions work and why they fail. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0019-8) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-04 /pmc/articles/PMC4491204/ /pubmed/26141716 http://dx.doi.org/10.1186/s40360-015-0019-8 Text en © Pollmann et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pollmann, André S.
Murphy, Andrea L.
Bergman, Joel C.
Gardner, David M.
Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
title Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
title_full Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
title_fullStr Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
title_full_unstemmed Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
title_short Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
title_sort deprescribing benzodiazepines and z-drugs in community-dwelling adults: a scoping review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491204/
https://www.ncbi.nlm.nih.gov/pubmed/26141716
http://dx.doi.org/10.1186/s40360-015-0019-8
work_keys_str_mv AT pollmannandres deprescribingbenzodiazepinesandzdrugsincommunitydwellingadultsascopingreview
AT murphyandreal deprescribingbenzodiazepinesandzdrugsincommunitydwellingadultsascopingreview
AT bergmanjoelc deprescribingbenzodiazepinesandzdrugsincommunitydwellingadultsascopingreview
AT gardnerdavidm deprescribingbenzodiazepinesandzdrugsincommunitydwellingadultsascopingreview